uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Experimentell och klinisk onkologi. Uppsala University Hospital, Department of Oncology.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Experimentell och klinisk onkologi. Uppsala University Hospital, Department of Oncology.ORCID-id: 0000-0002-0594-724x
Uppsala universitet, Science for Life Laboratory, SciLifeLab. Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Experimentell och klinisk onkologi.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Klinisk och experimentell patologi. Uppsala universitet, Science for Life Laboratory, SciLifeLab. (Fredrik Pontén)
Vise andre og tillknytning
2017 (engelsk)Inngår i: Journal of Cancer, ISSN 1837-9664, E-ISSN 1837-9664, Vol. 8, nr 19, s. 3975-3983Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background and aims: There is no established predictive marker for the treatment of renal cancer. Metastatic renal cell carcinoma (mRCC) patients are often treated with sunitinib, a tyrosine kinase inhibitor. Sunitinibs anti-cancer effect is at least partly mediated through interfering with angiogenesis. Our aim with the current study was to assess annexin A1 (ANXA1), which stimulates angiogenesis, as a predictive marker for sunitinib therapy in mRCC patients. Since previous studies have indicated a predictive potential for cubilin, we also investigated the predictivity of ANXA1 combined with cubilin.

Methods: ANXA1 expression was analysed in tumor tissue from a cohort of patients with advanced RCC (n= 139) using immunohistochemistry. Ninety-nine of the patients were treated with sunitinib in the first or second-line setting. Twenty-two of these were censored because of toxicity leading to the termination of treatment and the remaining (n= 77) were selected for the present study.

Results: Twenty-five (32%) out of seventy-seven of the tumors lacked ANXA1 in the cytoplasm. On statistical analyses using Kaplan-Meier method, aNXA1 negative tumors were significantly associated with a longer treatment benefit in terms of progression free survival (PFS). Overall survival was also significantly better for patients with ANXA1 negative tumors. The combined ANXA1 positive and cubilin negative expression could more accurately than ANXA1 alone define the group not benefitting from treatment.

Conclusions: Our results indicate that cytoplasmic expression of ANXA1 is a negative predictive marker for sunitinib therapy in mRCC patients. A possible explanation for this finding is that sunitinibs anti-angiogenic effect cannot overcome the pro-angiogenic drive from many ANXA1 proteins.

sted, utgiver, år, opplag, sider
2017. Vol. 8, nr 19, s. 3975-3983
Emneord [en]
Renal cancer, sunitinib, tissue microarray, predictive marker, ANXA1
HSV kategori
Forskningsprogram
Patologi
Identifikatorer
URN: urn:nbn:se:uu:diva-339521DOI: 10.7150/jca.20889ISI: 000418498600007PubMedID: 29187872OAI: oai:DiVA.org:uu-339521DiVA, id: diva2:1176296
Tilgjengelig fra: 2018-01-22 Laget: 2018-01-22 Sist oppdatert: 2019-04-02bibliografisk kontrollert
Inngår i avhandling
1. Intratumoral Predictive Markers in Metastatic Renal Cancer Patients
Åpne denne publikasjonen i ny fane eller vindu >>Intratumoral Predictive Markers in Metastatic Renal Cancer Patients
2018 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

There is no established predictive marker for the treatment of metastatic renal cell cancer (mRCC) patients. With a predictive marker, patients unlikely to respond could be selected upfront and offered other therapy options. Thereby, unnecessary toxicity could be avoided and costs would be reduced. Tyrosine kinase inhibitors (TKI) are the cornerstone in the treatment of mRCC. The aim of the thesis was to evaluate and hopefully define tumoral predictive markers for treatment with the common TKIs sunitinib and sorafenib.

The studies are based on immunohistochemical analyses of renal cancer tissues from 139 primary tumors sampled in a tissue microarray. Three proteins with a specific and differential expression in RCC were chosen in co-operation with the Human Protein Atlas project. Since TKIs block vascular endothelial growth factor receptors (VEGFR) on tumor vessels, angiogenesis associated proteins were also analysed as putative predictive biomarkers.

In two studies, the renal proteins cubilin (CUBN) and pyruvate kinase L/R (PKLR) were investigated. Our results indicate that these membranous proteins are positive predictive factors for sunitinib and sorafenib therapies. Patients with high membranous expressions of CUBN and PKLR respectively experienced significantly longer progression free survivals (PFS) and overall survivals (OS) compared to the other patients. Combining CUBN and PKLR negative tumors, a patient group with a particularly short PFS could be defined, possibly consisting of patients not benefitting at all from treatment with sunitinib or sorafenib.

Studies of tumoral annexin A1 (ANXA1) and epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) demonstrated predictive potential for sunitinib but not for sorafenib treatment. A low cytoplasmic expression of ANXA1 was significantly associated with longer PFS and OS in patients treated with sunitinib. A combined analysis with CUBN and ANXA1 expression indicated a higher predictive value than the expressions of either marker alone. We further observed that a high vascular endothelial expression of ELTD1 is predictive for a longer PFS and OS in sunitinib treated patients. The expressions of CD34 which is a marker of the number of vessels and the sunitinib target VEGFR2 failed to demonstrate significant associations with PFS.

To conclude, our real world studies indicate that CUBN, PKLR, ANXA1 and ELTD1 are potential tumoral biomarkers, to predict benefit from treatment with sunitinib (all four proteins) and sorafenib (CUBN and PKLR) in patients suffering from mRCC.

 

sted, utgiver, år, opplag, sider
Uppsala: Acta Universitatis Upsaliensis, 2018. s. 55
Serie
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1504
Emneord
Renal cell cancer, predictive marker, tyrosine kinase inhibitor, tissue microarray, cubilin, annexin A1, PKLR, ELTD1
HSV kategori
Forskningsprogram
Onkologi
Identifikatorer
urn:nbn:se:uu:diva-360251 (URN)978-91-513-0467-0 (ISBN)
Disputas
2018-12-01, Enghoffsalen, Akademiska Sjukhuset, ingång 50, Uppsala, 09:15 (svensk)
Opponent
Veileder
Tilgjengelig fra: 2018-11-07 Laget: 2018-10-09 Sist oppdatert: 2018-11-19

Open Access i DiVA

fulltext(1029 kB)41 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1029 kBChecksum SHA-512
bfffb36d237d7c5c810736de63ac7fadf26aaa5235330f195a51ad45a19e9908a29ff6bc38b174b269acf4565f748a65cf4848d0e171bd6e880b4d62a2516959
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Niinivirta, MarjutEnblad, GunillaEdqvist, Per-Henrik DPontén, FredrikDragomir, AncaUllenhag, Gustav

Søk i DiVA

Av forfatter/redaktør
Niinivirta, MarjutEnblad, GunillaEdqvist, Per-Henrik DPontén, FredrikDragomir, AncaUllenhag, Gustav
Av organisasjonen
I samme tidsskrift
Journal of Cancer

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 41 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 85 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf